Clinical Trials of Dementia With Lewy Bodies and Parkinson’s Disease Dementia
- First Online:
- Cite this article as:
- Aarsland, D., Ballard, C., Rongve, A. et al. Curr Neurol Neurosci Rep (2012) 12: 492. doi:10.1007/s11910-012-0290-7
- 1.1k Downloads
Despite the frequency and importance of dementia associated with Parkinson’s disease (PDD) and dementia with Lewy bodies (DLB), there is relatively little evidence on which to base treatment. Evidence from meta-analysis suggests that rivastigmine can improve cognition and functioning in PDD and also reduce risk of falling. There is also evidence supporting its use in DLB. Recent evidence suggests that memantine may also be effective, particularly for PDD, although evidence is more conflicting. Memantine may also improve parkinsonism and dyskinesias. Few clinical trials of cognition in PD without dementia exist, but there is preliminary evidence for atomoxetine, memantine, and piribedil. There is a lack of systematic evidence for the treatment of visual hallucinations and depression in PDD and DLB. In addition, there is a need for studies of whether potentially disease-modifying agents can prevent or delay the progression to dementia in PD.